Search Results - "Cohan, Stanley L"

Refine Results
  1. 1

    Daclizumab: Mechanisms of Action, Therapeutic Efficacy, Adverse Events and Its Uncovering the Potential Role of Innate Immune System Recruitment as a Treatment Strategy for Relapsing Multiple Sclerosis by Cohan, Stanley L, Lucassen, Elisabeth B, Romba, Meghan C, Linch, Stefanie N

    Published in Biomedicines (11-03-2019)
    “…Daclizumab (DAC) is a humanized, monoclonal antibody that blocks CD25, a critical element of the high-affinity interleukin-2 receptor (IL-2R). DAC HYP blockade…”
    Get full text
    Journal Article
  2. 2

    The Two Sides of Siponimod: Evidence for Brain and Immune Mechanisms in Multiple Sclerosis by Cohan, Stanley L., Benedict, Ralph H. B., Cree, Bruce A. C., DeLuca, John, Hua, Le H., Chun, Jerold

    Published in CNS drugs (01-07-2022)
    “…Siponimod is a selective sphingosine 1-phosphate receptor subtype 1 (S1P 1 ) and 5 (S1P 5 ) modulator approved in the United States and the European Union as…”
    Get full text
    Journal Article
  3. 3

    Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex) by Cohan, Stanley L., Hendin, Barry A., Reder, Anthony T., Smoot, Kyle, Avila, Robin, Mendoza, Jason P., Weinstock-Guttman, Bianca

    Published in CNS drugs (01-07-2021)
    “…Recombinant interferon (IFN) β-1b was approved by the US Food and Drug Administration as the first disease-modifying therapy (DMT) for multiple sclerosis (MS)…”
    Get full text
    Journal Article
  4. 4

    Efficacy of Ofatumumab and Teriflunomide in Patients With Relapsing MS From Racial/Ethnic Minority Groups: ASCLEPIOS I/II Subgroup Analyses by Williams, Mitzi J, Amezcua, Lilyana, Cohan, Stanley L, Cohen, Jeffrey A, Delgado, Silvia R, Hua, Le H, Lucassen, Elisabeth B, Piccolo, Rebecca S, Koulouris, Chloe R, Stankiewicz, James

    Published in Neurology (13-08-2024)
    “…Race and ethnicity may influence the efficacy of disease-modifying therapies in patients with multiple sclerosis (MS). Incidence of MS in ethnically diverse…”
    Get full text
    Journal Article
  5. 5

    Advancing Care and Outcomes for African American Patients With Multiple Sclerosis by Okai, Annette F., Howard, Annette M., Williams, Mitzi J., Brink, Justine D., Chen, Chiayi, Stuchiner, Tamela L., Baraban, Elizabeth, Jeong, Grace, Cohan, Stanley L.

    Published in Neurology (14-06-2022)
    “…Multiple sclerosis (MS) has historically been underdiagnosed and undertreated among African Americans. Recent evidence suggests that African Americans with MS…”
    Get full text
    Journal Article
  6. 6

    BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety by Fox, Robert J., Kita, Mariko, Cohan, Stanley L., Henson, Lily Jung, Zambrano, Javier, Scannevin, Robert H., O'Gorman, John, Novas, Mark, Dawson, Katherine T., Phillips, J. Theodore

    Published in Current medical research and opinion (01-02-2014)
    “…Abstract Background: Multiple sclerosis (MS) is a chronic inflammatory disease, affecting more than 2.5 million people worldwide with more 400,000 cases in the…”
    Get full text
    Journal Article
  7. 7
  8. 8

    Disutility of Cognitive Processing Speed (CPS) Impairment in the Context of Multiple Sclerosis: A Time Trade-Off (TTO) Elicitation Study by Benedict, Ralph H B, Vo, Pamela, Adlard, Nicholas, Grennan, Olwyn, Enstone, Ashley, Bridge, Daisy, Wyn, Robin, Cohan, Stanley L

    Published in ClinicoEconomics and outcomes research (01-01-2024)
    “…Cognitive impairment, especially relating to cognitive processing speed, is a major cause of disability in people with multiple sclerosis (MS). Utility values…”
    Get full text
    Journal Article
  9. 9
  10. 10

    Effects of baseline age and disease duration on the efficacy and safety of siponimod in patients with active SPMS: Post hoc analyses from the EXPAND study by Hua, Le H, Bar-Or, Amit, Cohan, Stanley L, Lublin, Fred D, Coyle, Patricia K, Cree, Bruce AC, Meng, Xiangyi, Su, Wendy, Cox, Gina Mavrikis, Fox, Robert J

    Published in Multiple sclerosis and related disorders (01-07-2023)
    “…Older age and longer disease duration (DD) may impact the effectiveness of disease-modifying therapies in patients with multiple sclerosis (MS). Siponimod is a…”
    Get full text
    Journal Article
  11. 11

    Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis by YEPES, M, SANDKVIST, M, WONG, M. K. K, COLEMAN, T. A, SMITH, E, COHAN, S. L, LAWRENCE, D. A

    Published in Blood (15-07-2000)
    “…Neuroserpin, a recently identified inhibitor of tissue-type plasminogen activator (tPA), is primarily localized to neurons within the central nervous system,…”
    Get full text
    Journal Article
  12. 12
  13. 13

    Eight-year immunogenicity and safety of interferon beta-1a-Avonex®treatment in patients with multiple sclerosis by Herndon, Robert M, Rudick, Richard A, Munschauer, Frederick E, Mass, Michele K, Salazar, Andres M, Coats, Michael E, Labutta, Robert, Richert, John R, Cohan, Stanley L, Genain, Claude, Goodkin, Donald, Toal, Martin, Riester, Katherine

    Published in Multiple sclerosis (01-08-2005)
    “…An open-label extension study of the phase III trial of intramuscular interferon beta-1a (IFNβ-1a-Avonex) was conducted to evaluate the immunogenicity and…”
    Get full text
    Journal Article
  14. 14
  15. 15

    Advancing Care and Outcomes for African American Patients With Multiple Sclerosis by Okai, Annette F., Howard, Annette M., Williams, Mitzi J., Brink, Justine D., Chen, Chiayi, Stuchiner, Tamela L., Baraban, Elizabeth, Jeong, Grace, Cohan, Stanley L.

    Published in Neurology (25-04-2022)
    “…Multiple sclerosis (MS) has historically been underdiagnosed and undertreated among African Americans. Recent evidence suggests that African Americans with MS…”
    Get full text
    Journal Article
  16. 16
  17. 17

    Disutility of Cognitive Processing Speed Elicitation Study by Benedict, Ralph H.B, Vo, Pamela, Adlard, Nicholas, Grennan, Olwyn, Enstone, Ashley, Bridge, Daisy, Wyn, Robin, Cohan, Stanley L

    Published in ClinicoEconomics and outcomes research (29-02-2024)
    “…Introduction: Cognitive impairment, especially relating to cognitive processing speed, is a major cause of disability in people with multiple sclerosis (MS)…”
    Get full text
    Journal Article
  18. 18

    Disutility of Cognitive Processing Speed by Adlard, Nicholas, Enstone, Ashley, Vo, Pamela, Bridge, Daisy, Wyn, Robin, Benedict, Ralph H.B, Grennan, Olwyn, Cohan, Stanley L

    Published in ClinicoEconomics and outcomes research (29-02-2024)
    “…Introduction: Cognitive impairment, especially relating to cognitive processing speed, is a major cause of disability in people with multiple sclerosis (MS)…”
    Get full text
    Journal Article
  19. 19
  20. 20

    2271 Safety and tolerability of conversion to siponimod with and without titration in patients with relapsing multiple sclerosis: interim results of the phase 3b EXCHANGE study by Simpson, Marion, Bar-Or, Amit, Weinstock-Guttman, Bianca, Mao-Draayer, Yang, Cruz, Linda-Ali, Cox, Gina Mavrikis, Cohan, Stanley L

    Published in BMJ neurology open (01-08-2022)
    “…ObjectivesEXCHANGE is a 6-month, open-label, single-arm trial of conversion to siponimod in patients with MS. Here we report interim analyses evaluating safety…”
    Get full text
    Journal Article